B. Riley Issues Positive Estimate for InfuSystem Earnings

Key Points

• Analysts at B. Riley have raised their Q3 2025 EPS estimate for InfuSystem Holdings to $0.10 per share, significantly up from their prior forecast of $0.02, and maintain a "Strong-Buy" rating.
• InfuSystem's full-year earnings consensus estimate is currently $0.15 per share, with projected future earnings of $0.30 EPS for FY2025 and $0.45 EPS for FY2026.
• Institutional investors control approximately 71.13% of InfuSystem's stock, with significant increases in positions by several firms during the second quarter.

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Analysts at B. Riley upped their Q3 2025 EPS estimates for InfuSystem in a research report issued on Tuesday, August 5th. B. Riley analyst A. Schock now forecasts that the company will earn $0.10 per share for the quarter, up from their previous forecast of $0.02. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem's Q4 2025 earnings at $0.09 EPS, FY2025 earnings at $0.30 EPS, Q3 2026 earnings at $0.16 EPS and FY2026 earnings at $0.45 EPS.

Several other research firms also recently issued reports on INFU. Wall Street Zen downgraded InfuSystem from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 14th. Roth Capital started coverage on InfuSystem in a research note on Tuesday, July 22nd. They issued a "buy" rating and a $12.00 target price for the company.

InfuSystem Stock Performance

Shares of INFU stock opened at $7.52 on Friday. The firm's 50 day moving average is $6.04 and its 200 day moving average is $6.17. The stock has a market capitalization of $158.04 million, a P/E ratio of 125.35 and a beta of 1.81. InfuSystem has a 12 month low of $4.61 and a 12 month high of $9.97. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. grew its position in InfuSystem by 38.9% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,772 shares of the company's stock worth $435,000 after buying an additional 19,554 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of InfuSystem during the 2nd quarter valued at about $294,000. Ground Swell Capital LLC purchased a new position in shares of InfuSystem during the second quarter worth about $135,000. CWM LLC increased its position in shares of InfuSystem by 1,160.1% in the second quarter. CWM LLC now owns 4,826 shares of the company's stock worth $30,000 after purchasing an additional 4,443 shares during the last quarter. Finally, Williams & Novak LLC purchased a new stake in InfuSystem in the second quarter valued at approximately $77,000. Institutional investors own 71.13% of the company's stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.